Key points
- Revenues down 7.9% to $7,026,000
- Loss from ordinary activities up 13.6% to $8,995,000
- No dividends paid or declared
- Amsulostat shows positive results in myelofibrosis and myelodysplastic syndromes
- SNT-4728 demonstrates neuroinflammation reduction in Parkinson's disease
Full summary
Syntara Ltd. has released its Annual Report for the year ended 30 June 2026, detailing financial performance and significant developments across its clinical pipeline. The company reported a 7.9% decrease in revenues from ordinary activities to $7,026,000, and a 13.6% increase in loss from ordinary activities after tax to $8,995,000. No dividends were paid or declared during the financial year. The report highlights substantial progress in the clinical development of amsulostat (SNT-5505) for myelofibrosis and myelodysplastic syndromes, with positive feedback from the FDA and Orphan Drug Designations. Additionally, Syntara's neuro-targeted anti-inflammatory therapy, SNT-4728, demonstrated a significant reduction in neuroinflammation in a Phase 2 study, marking an important step in the potential treatment of Parkinson's disease. The company also advanced its topical anti-fibrotic programs with promising early-stage clinical results.
Outlook
Syntara is optimistic about the future development of amsulostat and SNT-4728, with plans for further clinical trials to confirm efficacy and safety.